Procarta awarded £7.4M for microbial treatment
25 September 2019
The company, which has discovered a new type of antimicrobial that kills bacteria by blocking their gene expression, was awarded the funding by CARB-X, a global partnership dedicated to accelerating early antimicrobial R&D.
Further reading: Laboratory News
Author(s): Laboratory News
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
